Drug Profile

Rizatriptan intranasal - Benuvia Therapeutics

Alternative Names: Rizatriptan intranasal spray - INSYS Therapeutics; Rizatriptan nasal spray

Latest Information Update: 28 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator INSYS Therapeutics, Inc
Developer Benuvia Therapeutics; INSYS Therapeutics, Inc
Class Antimigraines; Small molecules; Triazoles; Tryptamines
Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

No development reported Migraine

Most Recent Events

28 Apr 2024 No recent reports of development identified for phase-I development in Migraine in USA (Intranasal, Spray)
27 Feb 2024 Chromocell Corporation in-licenses rizatriptan intranasal from Benuvia Therapeutics
27 Feb 2024 Chromocell Corporation plans a clinical trial in 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com